Shares of Singapore-listed medical technology firm UltraGreen.ai have plunged more than 50 per cent over the past nine months, falling from its December 2025 initial public offering price of US$1.45 to 68.5 US cents by Aug 31, 2026. The steep decline tests the Singapore Exchange’s strategy to attract non-REIT “new economy” listings, while throwing a spotlight on specialized risk disclosures and investor relations in complex sectors, according to market data and analysts.
SGX New Economy Push Faces Early Test After UltraGreen.ai Shares Halve
UltraGreen.ai’s US$400 million IPO on Dec 3, 2025, marked SGX’s largest non-REIT listing in eight years. The debut was central to the bourse’s push to diversify beyond traditional banking and real estate investment trusts. However, the subsequent share-price collapse has turned the medtech firm into an early bellwether for how investors price specialized new-economy companies on the exchange.
An SGX spokesperson told The Straits Times that the bourse does not comment on individual stocks. The spokesperson added that building a vibrant new-economy sector requires a long-term effort involving research coverage, active participation, and transparent engagement.
FDA Approval for Zydus Lifesciences Triggers US Market Concerns
UltraGreen.ai develops indocyanine green (ICG), a fluorescent dye surgeons use under near-infrared light to monitor blood flow, tissue structures, and tumours, primarily in gastrointestinal, oncological, and gallbladder procedures. According to its first-half 2026 results ended June 30, the company holds regulatory approvals in 46 countries, with the Americas generating 75 per cent of its US$87.2 million total revenue. Market estimates indicate the firm controls about 83 per cent of the US ICG market.
That dominance faced a direct challenge in August 2026 when Zydus Lifesciences secured US Food and Drug Administration approval for a competing ICG product. Because ICG lacks independent patent protection in the US, generic manufacturers can enter the market if they meet FDA reference standards. Zydus received a 180-day exclusivity period, though it faces forfeiture if it fails to launch commercially within 75 days of its Aug 4 approval.
“FDA approval is an important regulatory milestone, but does not, in itself, indicate commercial launch, customer adoption or market penetration,” UltraGreen.ai chief executive Ravinder Sajwan said in a statement on Aug 24, 2026. He noted the company would calibrate its response based on competitor pricing and distribution strategies.
Analysts Weigh In on Disclosure Regimes and Investor Education
The rapid share-price reaction highlights a learning curve for investors evaluating complex biotech and medtech business models. Amova Asset Management senior equity analyst Kathy Ng said that while the learning curve weighs on short-term sentiment, it remains a necessary hurdle for diversifying the Singapore market.
Ng noted that UltraGreen.ai management could have addressed potential US generic competition more proactively during its Aug 12 earnings release rather than leaving investors to learn through research reports. Conversely, Phillip Securities Research analyst Hashim Osman pointed out that UltraGreen.ai adequately outlined the lack of patent protection and other business risks in its November 2025 IPO prospectus.
Did you know? UltraGreen.ai spent over US$712,000 to repurchase one million shares from the open market on Aug 24, 2026, bringing its treasury holdings to 2.8 million shares, or 0.3 per cent of total issued shares, as part of management’s efforts to cushion the share-price drop.
Frequently Asked Questions
Why did UltraGreen.ai shares drop in 2026?
The shares fell after Zydus Lifesciences secured FDA approval in August 2026 for a generic indocyanine green (ICG) product, threatening UltraGreen.ai’s dominant market share in the United States.
Does UltraGreen.ai hold patents for its ICG product in the US?
No. According to the company’s IPO prospectus, ICG technology is not independently patented in the US, allowing regulatory-approved generic manufacturers to enter the market.
What is SGX’s stance on the share price decline?
An SGX spokesperson stated that the bourse does not comment on individual stocks and emphasized that building a new-economy ecosystem is a long-term effort requiring transparent engagement.